An interim analysis of an open-label extension study supported dupilumab use as a continuous long-term therapy for adults with atopic dermatitis (AD). Efficacy was sustained after transition from once-weekly (qw) to twice a week (q2w) dosing. Lisa A. Beck et al. aimed to assess the efficacy and safety of dupilumab intervention for up to 4 years in adults suffering from AD and its effectiveness in a subgroup of individuals who switched from the administration of dupilumab qw to q2w.

This study assessed 300 mg dupilumab qw or q2w in people formerly recruited in dupilumab trials for AD. The patients were transitioned from qw to q2w after protocol modification. Safety was the major outcome ascertained. An assessment of efficacy was also done. Out of 2677 patients, 352 patients accomplished week 204 (end of efficacy assessments) while 202 patients finished safety follow-up within week 244. The self-reported compliance was found to be 98.1%. The safety profile of dupilumab showed consistency with earlier reports.

The general treatment-associated side effects incorporated headache, injection-site reaction, conjunctivitis, oral herpes, upper respiratory tract infection, and nasopharyngitis.

The mean ± standard deviation (SD) Eczema Area and Severity Index (EASI), mean percent change from parent study baseline (PSBL); mean ± SD Pruritus Numerical Rating Scale (NRS) score, and mean percent change from PSBL were found to be 2.46 ± 3.98, −91.07%, 2.10 ± 1.83, and−68.74% respectively at week 204.

The effectiveness was retained in 226 people who switched from qw to q2w dosing. Dupilumab showed rapid enhancements in signs and symptoms of AD in the first couple of weeks of the intervention, followed by sustained effectiveness up to 204 weeks.